Genprex Inc
$ 4.27
-3.83%
07 Aug - close price
- Market Cap 2,241,900 USD
- Current Price $ 4.27
- High / Low $ 4.47 / 4.24
- Stock P/E N/A
- Book Value 41.18
- EPS -111.32
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.76 %
- ROE -1.61 %
- 52 Week High 1210.00
- 52 Week Low 4.00
About
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company is headquartered in Austin, Texas.
Analyst Target Price
$7.50
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-30 | 2025-11-14 | 2025-08-14 | 2025-04-07 | 2025-03-31 | 2024-11-13 | 2024-08-09 | 2024-05-15 | 2024-03-29 | 2023-11-14 | 2023-08-21 |
| Reported EPS | -14.1199 | -25.3334 | -5 | -8.47 | 2.58 | -0.4242 | -1353 | -3300 | -4059 | -3.96 | -0.13 | -0.15 |
| Estimated EPS | None | None | -0.65 | -0.74 | -0.39 | -0.39 | -3003 | -2530 | -2794 | -3.93 | -0.11 | -0.12 |
| Surprise | 0 | 0 | -4.35 | -7.73 | 2.97 | -0.0342 | 1650 | -770 | -1265 | -0.03 | -0.02 | -0.03 |
| Surprise Percentage | None% | None% | -669.2308% | -1044.5946% | 761.5385% | -8.7692% | 54.9451% | -30.4348% | -45.2756% | -0.7634% | -18.1818% | -25% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GNPX
2026-08-08 04:11:36
This article provides a brief update on Genprex Inc (GNPX) stock, stating that more news is coming soon regarding earnings, analyst ratings, and key developments. It also includes current stock data, showing a price of $4.270, a 3.83% decrease, and a market capitalization of $1.76 million.
2026-08-07 16:11:37
This article provides an earnings forecast for Genprex Inc (GNPX), noting that no earnings forecast score is currently available. It highlights an average analyst price target of $7.50, representing a significant upside potential, and lists peer comparisons based on analyst ratings. The article also includes basic financial information and frequently asked questions regarding the price target.
2026-08-06 21:09:49
Genprex (GNPX) has successfully regained compliance with Nasdaq's minimum bid price requirement. After receiving an exception on July 29, 2026, the company was formally notified on August 4, 2026, that it had met the $1.00 minimum bid price rule. The Nasdaq Hearings Panel will, however, retain jurisdiction until December 7, 2026, requiring Genprex to maintain its closing bid price at or above $1.00 daily.
2026-08-05 20:43:59
Genprex, Inc. (NASDAQ: GNPX) has announced that it has regained compliance with the Nasdaq Capital Market's $1.00 minimum bid price requirement. The Nasdaq Hearings Panel formally determined compliance but will retain jurisdiction over the company until December 7, 2026, requiring Genprex to maintain a closing bid price at or above $1.00 for every trading day until then. If the company breaches any other listing rule before that date, it will have seven days to present a cure plan or face potential delisting.
2026-08-04 12:41:29
This page provides live stock quotes and charts for Genprex Inc. (GNPX), including its current stock price and recent performance. It also indicates that there are currently no analyst ratings or earnings information available for the company. The page features various trading tools and educational resources, alongside promotional content for a stock trading bootcamp and AI-driven analysis.
2026-08-04 07:23:00
Genprex has announced a collaboration with Roche Diagnostics to validate biomarkers for patient selection in non-small cell lung cancer (NSCLC) clinical trials, specifically focusing on the TROP2 biomarker. Roche Diagnostics will use its TROP2 antibody to validate the assay, with studies expected to conclude by the end of the year. This partnership aims to accelerate patient identification and recruitment for NSCLC trials, leveraging Roche's expertise as an FDA breakthrough device designee for its AI-driven TROP2 diagnostic.
